Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report
Journal of Lasers in Medical Sciences,
Vol. 12 (2021),
13 February 2021
,
Page e12
Abstract
Introduction: Medication-related osteonecrosis of the jaws (MRONJ) corresponds to an adverse effect of the use of drugs such as Bisphosphonates and Denusomab. The management of MRONJ tends to be conservative, through the guidance of oral hygiene, antibiotic therapy and mouthwashes. However, the use of antimicrobial photodynamic therapy (aPDT) has shown promise in the treatment of these injuries. The purpose of this article is to report a case of MRONJ treatment associated with aPDT.
Case report: A 75-year-old patient, with a history of breast cancer and use of intravenous Zoledronic Acid, presented with bilateral MRONJ lesions in tuberosity on the right and left sides. Treatment was conservatively instituted with the use of aPDT as an adjuvant. After 12 aPDT sessions, complete regression of the lesion was observed. However, after two weeks, the presence of a new lesion was noted, this time in the anterior region of the maxilla. The same protocol previously established was followed and after two aPDT sessions, the patient returned with complete lesion regression.
Conclusion: The use of aPDT may represent an important adjuvant within a set of clinical protocols in the treatment of MRONJ.
DOI:10.34172/jlms.2021.12- Low-level laser therapy; MRONJ; Photodynamic therapy; Photobiomodulation; Bisphosphonates
How to Cite
References
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. Doi: 10.1016/j.joms.2014.04.031.
Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 2016 Mar;27(3):853-859. Doi: 10.1007/s00198-015-3335-3.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. Doi: 10.1016/s0278-2391(03)00720-1.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004 May;62(5):527-34. Doi: 10.1016/j.joms.2004.02.004.
Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010 May;68(5):959-63. Doi: 10.1016/j.joms.2009.10.010.
Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009 Feb;27(2):221–6. Doi: 10.1080/07357900802208608.
Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016 Jan 1;24(1):447–55. Doi: 10.1007/s00520-015-2904-5.
Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST, Kolk A, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence - A multi-centre study. J Cranio-Maxillofacial Surg. 2011 Jun;39(4):272–7. Doi: 10.1016/j.jcms.2010.05.009.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s. Doi: 10.1158/1078-0432.CCR-06-0931.
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: Medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1-2):136. Doi: 10.1007/s11657-013-0136-1.
Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg. 2018 Apr;73(2):100-109. Doi: 10.1080/17843286.2017.1348001.
Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo. 2017 May 22;69(1):9-15. doi: 10.4081/reumatismo.2017.983.
Ficarra G, Beninati F. Bisphosphonate - related osteonecrosis of the jaws: the point of view of the oral pathologist. Clin Cases Miner Bone Metab. 2007 Jan;4(1):53-7.
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012 May;23(5):1341-1347. Doi: 10.1093/annonc/mdr435.
Patel V, Mansi J, Ghosh S, Kwok J, Burke M, Reilly D, et al. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J. 2018 Jan 26;224(2):74-79. Doi: 10.1038/sj.bdj.2017.1039.
Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014 Apr;19(2):403-10. Doi: 10.1007/s10147-013-0561-6.
Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent. 2016 Mar-Apr;6(2):97-104. Doi: 10.4103/2231-0762.178742.
Zebic L, Patel V. Preventing medication-related osteonecrosis of the jaw. BMJ. 2019 May 8;365:l1733. Doi: 10.1136/bmj.l1733.
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019 Sep 1;37(25):2270-2290. Doi: 10.1200/JCO.19.01186.
O’Riordan K, Akilov OE, Hasan T. The potential for photodynamic therapy in the treatment of localized infections. Photodiagnosis Photodyn Ther. 2005 Dec;2(4):247-62. Doi: 10.1016/S1572-1000(05)00099-2.
Bisland SK, Burch S. Photodynamic therapy of diseased bone. Photodiagnosis Photodyn Ther. 2006 Sep;3(3):147-55. Doi: 10.1016/S1572-1000(06)00036-6.
de Castro MS, Ribeiro NV Jr, de Carli ML, Pereira AA, Sperandio FF, Hanemann JA. Photodynamically dealing with bisphosphonate-related osteonecrosis of the jaw: Successful case reports. Photodiagnosis Photodyn Ther. 2016 Dec;16:72-75. Doi: 10.1016/j.pdpdt.2016.08.007.
Eduardo CP, Bello-Silva MS, Ramalho KM, Lee EMR, Aranha ACC. A terapia fotodinâmica como benefício complementar na clínica odontológica. Rev Assoc Paul Cir 2015;69(3):226–35. [in portugue]
Heggendorn FL, Leite TC, Cunha KSG, Junior AS, Gonçalves LS, Da Costa KBFF, et al. Bisphosphonate-related osteonecrosis of the jaws: Report of a case using conservative protocol. Spec Care Dentist. 2016 Jan;36(1):43-7. Doi: 10.1111/scd.12143.
Ribeiro GH, Minamisako MC, Rath IB da S, Santos AMB, Simões A, Pereira KCR, et al. Osteoradionecrosis of the jaws: case series treated with adjuvant low-level laser therapy and antimicrobial photodynamic therapy. J Appl Oral Sci. 2018;26:e20170172. Doi: 10.1590/1678-7757-2017-0172.
de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. IEEE J Sel Top Quantum Electron. 2016 May-Jun;22(3):7000417. doi: 10.1109/JSTQE.2016.2561201.
Núñez SC, Garcez AS, Kato IT, Yoshimura TM, Gomes L, Baptista MS, et al. Effects of ionic strength on the antimicrobial photodynamic efficiency of methylene blue. Photochem Photobiol Sci. 2014 Mar;13(3):595-602. Doi: 10.1039/c3pp50325a.
Minamisako MC, Ribeiro GH, Lisboa ML, Mariela Rodríguez Cordeiro M, Grando LJ. Medication-Related Osteonecrosis of Jaws: A Low-Level Laser Therapy and Antimicrobial Photodynamic Therapy Case Approach. Case Rep Dent. 2016;2016:6267406. Doi: 10.1155/2016/6267406.
Eduardo FP, Bezinelli LM, Correa L. Odontologia na Oncologia. 1aed. São Paulo: Atheneu, 2019.
Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer therapies and jaw necrosis. Br Dent J. 2015 Sep 11;219(5):203-7. Doi: 10.1038/sj.bdj.2015.680
Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012 Dec;7(12):1823-1829. Doi: 10.1097/JTO.0b013e31826aec2b.
Goodday RH. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw. Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):527-36. Doi: 10.1016/j.coms.2015.06.006.
Grisar K, Schol M, Schoenaers J, Dormaar T, Coropciuc R, Vander Poorten V, et al. Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences. Int J Oral Maxillofac Surg. 2016 Dec;45(12):1592-1599. Doi: 10.1016/j.ijom.2016.06.016.
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018 Sep;69:177-187. Doi: 10.1016/j.ctrv.2018.06.007.
de Sales Lima MV, Rizzato J, Gracindo Marques DV, Kitakawa D, da Silva Peralta F, Prado Scherma A, et al. Denosumab Related Osteonecrosis of Jaw: a Case Report. J Oral Maxillofac Res. 2018 Dec 30;9(4):e5. Doi: 10.5037/jomr.2018.9405.
Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review. J Oral Biosci. 2019 Jun;61(2):99-104. Doi: 10.1016/j.job.2019.03.005.
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Feb;127(2):117-135. Doi: 10.1016/j.oooo.2018.09.008.
Andrade IP, Xavier KBC, Nunes APF, Fardin RF. Concentração inibitória mínina de antissépticos bucais em microorganismos da cavidade oral. RBPS [Internet]. 2011Sep.10 [cited 2021Feb.23];. Available from: https://periodicos.ufes.br/rbps/article/view/1761
Bulloch MN, Baccas JT, Arnold S. Clindamycin-induced hypersensitivity reaction. Infection. 2016 Jun;44(3):357-9. Doi: 10.1007/s15010-015-0826-2.
- Abstract Viewed: 1072 times
- PDF Downloaded: 543 times